STAMBP and melanoma: Initially, radiolabeled alpha-melanocyte-stimulating hormone (α-MSH) peptides were used to target MC1Rs for melanoma imaging [84–90], whereas radiolabeled RGD peptides have been utilized to targeting the αvβ3 integrin receptors for melanoma detection [107–112], respectively.